Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis (NCT04415372) | Clinical Trial Compass
By InvitationNot Applicable
Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis
United States75 participantsStarted 2021-11-19
Plain-language summary
The overall purpose of this research is to determine whether new macromolecular measures optimized for whole brain (gray matter and white matter) magnetic resonance imaging (MRI), predict neuro-cognitive impairment in multiple sclerosis (MS) patients.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Clinically definite MS
* Adult age 18 to 60
Exclusion Criteria:
* Contraindication to MRI
* Changes in MS therapy in the last 6 months
* Less than 6 weeks after relapse or corticosteroid use
* Currently taking medication that may affect cognition (e.g. donepezil, rivastigmine, adderall)
* History of significant alcohol or drug abuse
* Current or recent significant migraines
* Confounding neurological or cognitive disorders or deficits (stroke, Parkinson's disease, Alzheimer's disease, epilepsy)
* Sensory or physical impairments that might interfere significantly with cognitive testing
* History of developmental or learning disability or attention-deficit/hyperactivity disorder.\\
Exclusion Criteria for Healthy Controls:
* history of alcohol/drug abuse
* history of migraines
* developmental or learning disability/attention-deficit/hyperactivity disorder
* currently pregnant/breastfeeding
What they're measuring
1
Measurement of macromolecular proton content (MPC) by Magnetic resonance imaging